EuroIntervention PCRonline - Connecting with the community


Subclinical leaflet thrombosis – a concern, but also an issue?

The Heart Centre, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark


Bioprosthetic prostheses are increasingly used for surgical aortic valve replacement (SAVR) in patients with stenotic aortic valves1, due to the avoidance of oral anticoagulation therapy (OAC) – particularly in patients with an increased bleeding risk. In addition, transcatheter aortic valve implantation (TAVI) has, during the last decade, rapidly expanded as an alternative to SAVR in patients at increased surgical risk. However, bioprosthetic heart valves have limited longevity and a constant risk of structural valve deterioration (SVD), including valve thrombosis. Despite the fact that crimping of the heart valve prosthesis…

– OR –